ReviewMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026
Overview of the DREADDs chemogenetics and the patent landscape of their actuators.
Review in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The ability to manipulate specific neural populations with high temporal and spatial precision has revolutionized our understanding of brain-behavior relationships. Among the most versatile tools in the chemogenetic arsenal are Designer Receptors Exclusively Activated by Designer Drugs (DREADDs). By introducing engineered proteins that remain inert to endogenous neurotransmitters but react potently to synthetic actuators, chemogenetics provides unparalleled control over neural circuits in vivo. With the field evolving, new designer ligands and designer receptors have been reported. This review provides an update on the latest advances in DREADD chemogenetics, focusing on the development of next-generation ligands and the patent landscape innovations driving the next era of precision neuromodulation.
Indexed as
Identifiers
42545463What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.